• Alzheimer’s is a leading cause of dementia in adults in the United States
• IGC’s cannabis-based drug may reverse the buildup of beta-amyloid plaque
• Hyalolex and other phytocannabinoid-based drugs are fueling potential for the company’s market valuation growth

Alzheimer’s disease is currently the sixth-leading cause of death in the nation and the most common cause of dementia in older individuals. The chronic neurodegenerative disease has had no cure or effective treatment for reducing its symptoms, but India Globalization Capital, Inc. (NYSE MKT: IGC) is seeking to change that with a potential blockbuster drug. Hyalolex, otherwise known as IGC-AD1, is a cannabis-based drug that has the potential to reduce beta-amyloid plaque buildup in the brain, with the possibility of lessening some of the symptoms of the disease. A recent article focused on the efforts of IGC and other pharmaceutical companies to develop cannabinoid-based therapies for a range of serious diseases can be found at http://dtn.fm/7OmXx.

In June 2017, the company announced its acquisition of exclusive rights, from the University of South Florida, for a tetrahydrocannabinol (THC)-based treatment. A study conducted at the university found that the cannabis extract reversed beta-amyloid accumulation in mice. Subsequently, IGC became the exclusive licensee of the patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” It involves a new pathway for low doses of the compound to bind to the plaque and prevent it from collecting on nerve cells (the process thought to result in cognitive decline).

Hyalolex isn’t the only pipeline drug driving the potential for IGC’s market valuation growth. Several cannabis companies have seen hundreds of millions, even billions, of dollars in market valuations with phytocannabinoid-based therapies. Plus, IGC isn’t limiting its drug development to novel Alzheimer’s treatments. Others include Serosapse, for Parkinson’s disease; Natrinol, to treat cachexia in AIDS and cancer patients; and Caesafin, a combination therapy that targets dogs and cats with seizures.

Currently, IGC is the only publicly-traded pharmaceutical cannabis stock that addresses Alzheimer’s disease. However, a number of studies suggest the therapeutic value of treating the disease with cannabis-based drugs. These include studies of how THC molecules can potentially bind to and break up amyloid-beta proteins and other analysis suggesting positive results and that patients for the most part tolerate the effects of THC. A study on mice, conducted in partnership between the University of Bonn and the Hebrew University of Jerusalem, found low-doses of cannabis improved the memory and increased nerve cell links in older subjects.

The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.

For more information about India Globalization Capital and its groundbreaking phytocannabinoid therapies for Alzheimer’s and other diseases, visit www.IGCInc.us

• Avoids federal legal issues by sourcing hemp grown outside U.S. and focusing on federally legal cannabidiol (CBD)
• Targets rapidly developing cannabis market, with cannabidiol alone expected to reach over $2 billion by 2020
• Distribution already covers all 50 states, and is growing internationally

PotNetwork Holdings, Inc. (OTC: POTN), based in Fort Lauderdale, Florida, is a holding company. The company’s First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

• Diamond CBD Gummies – Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
• Chill Gummies – Chill gummies are more robust than its counterpart, the “Relax” gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
• CBD Liquid Gold – CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
• Blue CBD – Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
• Relax Gummies – Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that’s looking for a lighter effect without sacrificing quality or taste.
• Premium Hemp Liquid Pet – CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
• CBD Re-Leaf – Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
• Relax Extreme CBD – Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
• CBD Double Shot – CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it’s that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
• Chill Pill – CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions.

For more information, visit the company’s website at www.PotNetworkHolding.com

Let us hear your thoughts: PotNetwork Holdings, Inc. Message Board

• The precast concrete manufacturer, for the half ended the same date, recorded a 14.1% rise in revenues and a 377% spike in net income
• Safety barrier project in Northern Virginia has SMID working at full capacity seven days a week to meet deadlines
• Company has backlog of $30.2 million, optimistic about profitable performance in 2018

Smith-Midland Corporation (OTCQX: SMID), a precast concrete manufacturer, has announced (http://dtn.fm/Rr9pC) an 11.4% jump in sales for the quarter ended June 30, 2017, and a 69.9% increase in net income. Sales rose to $10.7 million for the quarter, compared to $9.6 million for the same period last year. In the most recent quarter, net income increased to $711,653, compared to $418,924 the same period in 2016.

For the six months ended June 30, 2017, the company generated revenues of $20.2 million, 14.1% higher than the $17.7 million during the same period a year ago. Net income rose to $1,568,854, a 377% jump from $329,148 during the same period the prior year. In its SEC 10-Q filing of August 10, 2017 (http://dtn.fm/XMP5g), the company attributed the gains to a lower cost of goods and increases in sales of high margin products.

Smith-Midland, based in Midland, Virginia, is a precast concrete company which specializes in producing, renting, licensing and selling products for the construction, utilities and transportation industries.

In a news release, Rodney Smith, chairman and chief executive officer, said, “Smith-Midland’s earnings continue to demonstrate our ability to generate profitable returns on a quarter by quarter basis. Lean process improvements and our commitment to customer satisfaction have helped drive quality performance to the bottom line results. With an increase in the current backlog to $30.2 million, the company is well positioned to continue its profitability in 2018.”

He added that Smith-Midland has a purchase order for the safety barrier on the I-395 high occupancy toll lane project in Northern Virginia, as a result the company is working seven days a week to meet the delivery dates required within the contract. He also noted that Smith-Midland is actively bidding for other large safety projects, as well as highway safety wall projects.

For more information, visit the company’s website at www.SmithMidland.com

• Industry leader projects cryptocurrency bitcoin, which has achieved $4,000 price, can reach $100,000 within five years
• Company provides processing solution for “unbankable” risk markets, such as legalized cannabis
• SinglePoint releases new investor relations kit that details its acquisition strategy, profiles key executives (http://dtn.fm/eZ4HE)

SinglePoint, Inc. (OTC: SING) finds itself at the intersection of two fast-growth markets: the cryptocurrency bitcoin and legalized cannabis. Bitcoin prices recently surged past $4,000 and are projected by industry leader Wu Jihan, founder of bitcoin miner Bitmain, to possibly reach $100,000 within five years, according to a video by Bloomberg L.P. (http://dtn.fm/9mHDH). At the same time, research from Cowen & Company estimates that legalized cannabis sales could reach $50 billion by 2026, according to a Bloomberg L.P. Markets report (http://dtn.fm/U5Nle).

SinglePoint is a high-technology company offering payment processing solutions in high risk markets, such as the legal cannabis industry. That market operates independently of conventional banks. In a joint venture with First Bitcoin Capital, Inc. (OTC: BITCF), SinglePoint uses its own proprietary technology to process transactions in bitcoins for the “unbankable” cannabis market. The company has also made acquisitions within the cannabis industry, including SingleSeed, Convectium and Discount Indoor Garden Supply (DIGS).

Cannnabis dispensaries are seeking a solution for customer transactions which are federally limited in their payment options, requiring payments independent of traditional banks and the FDIC. Bitcoin represents a payment option to dispensaries which are concerned about doing business in a cash-only environment. SinglePoint gives those dispensaries a bitcoin solution (http://dtn.fm/SeI4U). Further, SinglePoint’s acquisitions in the cannabis industry also reinforce its involvement within that fast growing business.

SinglePoint recently released a 16-page investor relations kit, which profiles key executives in the company, as well as detailing the firm’s marketing strategy, acquisitions and diversification into horizontal markets.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Core operations transitioned to phytocannabinoid-based therapies
• Four trial candidates targeting chronic pain, Alzheimer’s and other conditions
• Unique approach combining existing therapies with cannabinoids

India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments. Currently, the Maryland-based corporation has a pipeline of cannabis-based combination candidates under development to treat Alzheimer’s disease, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy. Supporting this effort, the company has put together a robust intellectual property (IP) portfolio. IGC intends nothing less than to become a leading specialty provider of phytocannabinoid-based pharmaceuticals and complimentary alternative medicine (CAM) nutraceutical products. Operating in the world’s fastest growing industry (cannabis) with its novel ‘something old, something new’ approach, IGC could soon expect its valuation to rise in line with peers like Corbus Pharmaceuticals (NASDAQ: CRBP), Anavex Life Sciences (NASDAQ: AVXL) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

IGC recently disposed of its low-margin iron ore and electronic trading businesses. With that divestment, the company is now focused on its long-term goal of becoming a heavyweight in the cannabis space. To achieve its objective of being a major player of cannabinoid combination therapies, IGC is actively engaged in planning the development pathways for its four product candidates.

IGC-501 heads IGC’s quartet of pipeline candidates. In September 2015, the company filed a Patent Cooperation Treaty (PCT) application for the therapy, which addresses neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. At present, such indications tend to be treated with opioids, which are notoriously addictive. However, the alarming rise and devastating effects of opioid abuse are driving the search for less pernicious alternatives. In the U.S. alone, this presents a market opportunity of around $25 billion.

A PCT filing has also been made for IGC-502, designed to treat canine seizures, which affect about five percent of dogs. Additionally, in August 2016, the company filed for a therapy to treat cachexia, which it has designated IGC-504. Also known as wasting syndrome, cachexia affects about 1.3 million in the U.S. It is a condition that’s typically associated with cancer, multiple sclerosis (MS), Parkinson’s, and HIV/AIDS.

In June 2017, IGC announced it had entered into a definitive agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” This agreement gives IGC a way to enter a huge market for what has been called ‘America’s most expensive disease.’ For 2017, Medicare and Medicaid expenditures for treating Alzheimer’s are expected to reach $175 billion. Currently, over 5.3 million Americans suffer from the condition, and that number is expected to double over the next 20 years.

The drug candidate IGC-ADI explores an alternative way delta 9-tetrahydrocannabinol (THC) interacts with the human body. Several pathways have already been identified, including binding to the CB1 receptor, anti-oxidative effects, and others, but IGC-ADI works through a different molecular pathway that allows low doses of THC to bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which causes the cognitive decline that results in Alzheimer’s disease. If approved, this patent will give IGC a significant proprietary interest in a unique way to treat Alzheimer’s disease. THC is the psychotropic phytocannabinoid mainly responsible for the ‘high’ of cannabis, although, it must be noted, other cannabinoids such as cannabinol (CBN) and tetrahydrocannabivarin (THCV) are psychotropic. The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a Phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.

The same is true of companies developing cannabinoid-based treatments. Corbus Pharmaceuticals, which presently has programs assessing its oral endocannabinoid-mimetic drug candidate for treating a variety of ailments, has a current market cap of around $310 million, and Zynerba, which is also developing synthetic cannabinoids, has a market cap of about $235 million at present. IGC, trading presently at $0.40, has a market cap of about $12 million, a valuation that is unlikely to stay that low for long.

For more information, visit the company’s website at www.IGCInc.us

• Poised for rapid revenue development following acquisition of MediaPlay
• Agreements in place with leading application stores to fast-track applications
• Company had $589,000 in revenues in 2016 and was able to eliminate more than $500,000 in corporate debt

Technology development and incubation acceleration company AppSwarm, Inc. (OTC: SWRM) has announced its acquisition of MediaPlay, a multiplatform games publisher and developer (http://dtn.fm/QM3ia). The company has further announced the creation of two AppSwarm divisions.

Assets purchased as part of the acquisition include:

• Games in-house
• Rights to games currently in negotiations
• Pending letters of intent
• Pending distribution agreements
• Work-for-hire contracts

MediaPlay has a special focus on free-to-play mobile games and is led by a core team composed of veterans of the game industry who have made successful exits in previous ventures and have held executive positions with some of the world’s largest gaming companies, such as Electronic Arts, Kabam and Activision. Collectively, the MediaPlay team is responsible for the launch of more than seven companies.

Historically, MediaPlay’s team has created organic growth by developing some of its own products, as well as through third-party acquisitions of branded games. The MediaPlay team has had tremendous ongoing success and has had its games featured by Apple and Google multiple times. The team executed a three-game development and publishing agreement with Discovery Networks in 2016 and has made subsequent deals with Valiant Entertainment and other brands.

AppSwarm anticipates rapid revenue development within the next 24 months as a result of this acquisition. MediaPlay brings an acute focus on nurtured relationships and international contacts, as well as a proven ability to bring about major corporate developments and publishing agreements.

The acquisition further enables AppSwarm to form two distinct but synergistic gaming divisions and revenue streams. The company’s current efforts will be focused on the application Incubation and Acquisition Division, which includes gaming opportunities, interactive developments and e-commerce business solutions.

Focused on partnering with app developers, AppSwarm is engaged in accelerating the development of free-to-play mobile games and fast-tracking them to the market. The company partners with game developers through joint ventures, royalty agreements, marketing partnerships and outright purchases.

AppSwarm actively reaches out to budding, entrepreneurial-minded application developers with great ideas who lack the knowledge to effectively market their products. When the company identifies an application with potential, the person or firm that created the app is approached by AppSwarm for the purposes of negotiating a stock purchase agreement, royalty agreement, joint venture, partnership or outright purchase.

AppSwarm has enviable financial resources to help market applications in the most effective ways. The company uses all forms of social marketing, along with traditional marketing, to get an app before as many eyes as possible. AppSwarm further has agreements in place with the foremost application stores, enabling the company to fast-track its applications.

In 2016, AppSwarm had revenues of $589,000, and the company was able to eliminate well over $500,000 in corporate debt. This enabled AppSwarm to commence 2017 with the momentum to complete synergistic mergers and acquisitions, such as the acquisition of MediaPlay.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Payment solutions for cannabis industry
• Operator of cryptocurrency exchange
• Bitcoin payment solutions for retailers

In its latest initiatives, SinglePoint, Inc. (OTC: SING) is showing that innovation, like politics, makes strange bedfellows. This diversified holding company specializing in acquisitions of small to mid-sized companies, with an emphasis on new technologies, is planning a marriage of cannabis and cryptocurrencies, both of which are rapidly growing opportunities. The company is developing a payment processing solution utilizing cryptocurrencies that is likely to find early application in the cannabis industry. Using its recently acquired $Weed and other cryptocurrencies, SinglePoint wants to help the cannabis industry solve its payment problems.

Although licensed by their state authorities, medical marijuana dispensaries and other cannabis retailers find it difficult to maintain merchant banking accounts at federally regulated financial institutions. The latter, fearful of violating the Controlled Substances Act, will typically cease operating an account if they discover it is associated with a business that ‘touches the plant’. Consequently, cannabis businesses are forced to deal in cash and face the attendant risk of burglaries and holdups. Additionally, customers cannot use their debit and credit cards, and all this because the regular financial system is federally regulated.

Cryptocurrencies, however, are not, and so they offer a ready-made solution to payment problems confronting high risk industries. The best known of these is undoubtedly bitcoin, the fortunes of which continue to improve, according to a recent MarketWatch report (http://dtn.fm/btcW9). Its authors discuss the high positive correlation between bitcoin prices and Google search trends for the word ‘bitcoin’, dubbed ‘a virtuous Satoshi cycle’ by Chris Burniske, who first observed it. Burniske is a bitcoin expert, previously a blockchain analyst at ARK Invest. Recent bitcoin prices have been stratospheric, with the price of a single bitcoin hitting a record high of $4,483.55 recently. Consumers who opt for a cryptocurrency wallet (part of the SinglePoint payment solution) will not only increase their payment options but their holdings of an asset that just keeps climbing in value.

SinglePoint has been working on a cryptocurrency solution for some time. Early in August, the company announced its purchase of the $Weed cryptocurrency from joint venture partner First Bitcoin Capital (OTC: BITCF). Known also as WeedCoin, the digital currency is currently listed on three exchanges, and SinglePoint intends to list and market the currency on more exchanges in the future. The recent initial coin offering (ICO) launch for the $Weed cryptocurrency resulted in an impressive market cap of close to $60 million.

In addition, SinglePoint intends to market its $Weed wallet to cannabis customers before they even set foot in the store. If successful, these efforts will address one of the largest barriers relating to the use of cryptocurrency at cannabis retail stores, i.e., consumers without a wallet who want to make a purchase. SinglePoint believes that, with proper execution, users of its $Weed cryptocurrency could enjoy a similar experience to the one offered to users of Starbucks’ mobile payment system, with payments completed through a simple scan of a barcode on the user’s smartphone or tablet.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Booking engine as a B2B product set to drive growth
• NASDAQ listing in sight
• Fresh capital injection of $3 million

With the completion of its proprietary booking engine late last year, Monaker Group, Inc. (OTCQB: MKGI) has moved closer to realizing its motto: Travel Made Easy. Now the technology-driven travel company is intensifying its focus on delivering innovation to the alternative lodging rental (ALR) market and, to do so, has bolstered its balance sheet. The company has closed a round of financing with institutional and accredited investors (http://dtn.fm/i2DGk). The funds are earmarked to expand the B2B white label potential of the booking engine and to get the company ready for a listing on the NASDAQ.

Booking engines are the latest iteration by the travel industry to increase access and choice to consumers. They represent the current stage of developments that began in the post-WWII era, when American Airlines (AA) developed the industry’s first automated booking system. Its esoteric name, “Electromechanical Reservisor” (ER), might have puzzled the average traveler if he were allowed access to it, but he was not. Neither were travel agents. Only AA’s airline personnel could access the ER. The airline followed up the ER system, in 1953, with the tongue-twisting Semi-Automatic Business Research Environment reservation system (SABRE).

AA’s success in the reservation business meant that other airlines needed to follow suit to remain competitive. As a result, United Airlines launched Apollo; Delta Airlines came up with DATAS; and Trans World Airlines responded with PARS. These were all proprietary, silo systems, owned and used exclusively by the airlines that developed them, and they were not linked to each other.

By the 1970s, airlines were seeing the advantages of allowing travel agents access to their systems. As a result, the in-house reservation systems morphed into what became known as computer reservation systems (CRS), through which travel agents could query and make reservations. Soon, third party entities hit on the idea of linking separate computer reservation systems, and global distribution systems (GDS) were born. GDS offered travel agents access to the inventory of all the main airlines. Now that agents were part and parcel of the network, the obvious next step was to offer the traveler himself access through a booking engine.

Through a booking engine, a would-be traveler can specify his or her travel requirements such as point of departure, departure date, destination, return date and class of travel. In response, the booking engine will offer airline seats, hotel rooms, alternative accommodation and a variety of related offerings that fit the bill. This is definitely travel made easy.

Monaker expects that most of its growth in the future will come from offering its booking engine as a B2B white label “Alternative Lodging” “Vacation Rental” product to established providers, such as online travel agencies (OTAs) and cruise providers, particularly since it offers “Instant Booking”. Instant Booking allows travelers to initiate a booking and receive an instant confirmation.

Monaker recently completed a private placement of equity with a group of institutional and accredited individual investors for gross proceeds of $3 million. Certain insiders and board members also participated in the offering, representing $635,000, or approximately 21 percent of the offered amount. Part of the proceeds will go toward further development of its booking engine, which forms the core of Monaker’s alternative lodging rental platform. The fresh capital will also facilitate the company’s efforts to be listed on the NASDAQ, which are presently underway.

For more information, visit the company’s website at www.MonakerGroup.com

• Disruptive, patented technology is set to revolutionize the edible cannabis market
• Company has patent applications in 45 countries, including 18 applications in the U.S.
• Technology is patent-protected for CBD and all other non-psychoactive cannabinoids, with patents pending for THC, other psychoactive cannabinoids, NSAIDs, nicotine and other molecules

A common complaint among the consumers of cannabis edibles is an unpleasant taste that can often be detected, but that unpleasant taste and other inadequacies of cannabis edibles are being overcome thanks to the incredible innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP).

Lexaria is literally bringing new flavor to the marijuana industry with its disruptive process, which masks the unpleasant taste associated with cannabis. Lexaria’s lipophilic enhancement technology also changes the way cannabinoids enter the body; substantially speeds up the time frame in which tetrahydrocannabinol (THC) effects can be felt after consuming a cannabinoid edible; and increases bio-absorption by up to 10 times, making the absorption from cannabis edibles equal to the absorption from inhaled cannabis.

Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like smoking, for greater effectiveness. Lexaria’s proprietary technology for better delivery of bioactive compounds solves the problem of poor absorption, increasing the bio-absorption of cannabis edibles by between five and tenfold. The effects of the THC from an edible product created using Lexaria’s patented process are also felt much more quickly—taking effect within 15-20 minutes as opposed to one to two hours.

The possibilities enabled by Lexaria’s technology are multifold and exciting. For instance, excessive amounts of sugar have previously had to be included in cannabis edibles to mask the unwanted taste, but because Lexaria’s technology eliminates that undesirable flavor, zero-sugar formats are now possible for cannabinoid edibles.

Lexaria’s process involves taking the healthy cocktail of molecules found in the company’s organically sourced hemp and infusing those molecules inside the molecules of other ingredients. Lexaria works with lipids, because the endocannabinoid system in the human body is lipid-based. The company has found its method to be a more efficient means of delivering hemp oil ingredients to the body, making a small amount of hemp seed oil inside a Lexaria product equal to a great deal of hemp oil delivered via a product that wasn’t created using the company’s revolutionary technology.

Lexaria’s pioneering technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Patents are further pending for THC and other psychoactive cannabinoids, along with nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. In the United States, 18 patent applications have been filed, and international and national patent filings have been made in 44 other countries.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• One of first licensed medical cannabis producers in Canada
• $15 million equity investment starts construction of new 50,000 square foot facility
• Production to quadruple in booming market

Legal since 2001, medical cannabis operations in Canada changed dramatically about a year ago when the Access to Cannabis for Medical Purposes Regulations (ACMPR) went into effect. Health Canada now strictly oversees licensing, monitoring and compliance of commercial medical cannabis producers. Health Canada conducts thorough reviews of applications to ensure compliance with the regulations and works closely with producers once licensed to monitor and ensure compliance with such strictures as personnel security measures, good production practices, packaging, shipping, record keeping and import and export requirements. Licenses are difficult to acquire, and frequent inspections hold producers to stringent standards.

One of the very first licensed producers and a pioneer in Canadian medical cannabis, ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) has always held to meticulous specifications in the production of its pharmaceutical grade, plant-based medicines. Maintaining standards designed to exceed government requirements, ABcann grows plants only in small batches in order to create controllable, consistent and predictable yields. The plants are nurtured in controlled environmental chambers to deliver dependable results with each harvest. Chemical and pesticide free, ABcann produces medical cannabis that effectuates the same medical response with every use.

Medical cannabis business is booming in Canada. The number of medical marijuana patients continues to grow rapidly, increasing nearly 30 percent in the first quarter of this year, while sales of medical cannabis increased over 24 percent from last year. The growth trajectory shows no signs of slowing, and, given the licensing process and stringent inspections, licensed producers already in production are well positioned to reap substantial rewards.

Given ABcann’s underlying value, the recent announcement by Cannabis Wheaton Income Corp. (TSX.V: CBW) comes as little surprise. In a July 28th press release, Cannabis Wheaton, which invests in and supports a wide range of cannabis cultivation companies, announced Exchange approval for its purchase of $15 million of common shares of ABcann Global at $2.25 per share. This initial investment is part of a larger phased investment for the construction of an additional 50,000 square feet of pure cultivation space next to ABcann’s current 14,000 square foot cannabis cultivation facility in Ontario, Canada.

With a market capitalization around $82 million, ABcann presents great value for Cannabis Wheaton. Other Canadian licensed producers carry much higher market valuations. Emblem Corp., with nearly the same sized facility as ABcann, trades around the two dollar mark and carries a $170+ million market cap. Supreme Pharmaceuticals has a $250 million cap, and Hydropothecary Corporation maintains a $150 million cap, even after a voluntary stop-sale / stop-shipment when evidence of unapproved fungicide was found in its products. Cannabis Wheaton’s minority stake in ABcann looks to be a steal.

ABcann has already invested over $20 million in ongoing operations and international expansion plans. The company currently owns and operates a 14,000 square foot state-of-the-art facility. It also owns an adjoining 50 acres of land that’s slated for construction of the new 50,000 square foot production facility financed by Cannabis Wheaton’s equity investment. The additional cultivation space at the new facility is anticipated to provide Cannabis Wheaton with an estimated eight million grams of cannabis per year, while its equity position in ABcann should pay off handsomely as well.

ABcann’s proprietary cultivation methods already produce high quality cannabis with industry leading yields, and this latest announcement is a testament to ABcann’s future. The Canadian government recently stated that it will press ahead in 2017 with plans to legalize marijuana for adult recreational use. That market is expected to be worth $5 billion a year by 2020, according to leading industry analysts. This latest investment in ABcann appears both well timed and financially prescient.

For more information, visit the company’s website at www.ABcann.ca

Let us hear your thoughts: ABcann Global Corp. Message Board